www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

VX 765

产品编号: D51698

CAS: 273404-37-8

分子式: C24H33ClN4O6

纯度: ≥98%

InChi: InChI=1S/C24H33ClN4O6/c1-5-34-23-16(12-18(30)35-23)27-21(32)17-7-6-10-29(17)22(33)19(24(2,3)4)28-20(31)13-8-9-15(26)14(25)11-13/h8-9,11,16-17,19,23H,5-7,10,12,26H2,1-4H3,(H,27,32)(H,28,31)/t16-,17-,19+,23+/m0/s1

InChi Key: SJDDOCKBXFJEJB-MOKWFATOSA-N

Smiles: CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)C1C=CC(N)=C(Cl)C=1)C(C)(C)C

外观: 固体粉末

作用通路: Caspase

溶解性: soluble in DMSO, not soluble in water.

保存条件: Store in dry, dark place for one year.

产品介绍: VX 765, is designed to inhibit Caspase, which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18. VX-765 has been shown to inhibit acute seizures in preclinical models. In addition, VX-765 has shown activity in preclinical models of chronic epilepsy. VX-765 had been dosed in over 100 patients in phase-I and phase-IIa clinical trials relating to other diseases, including a 28-day phase-IIa clinical trial in patients with psoriasis. It has completed the treatment phase of a phase-IIa clinical trial of VX-765 that enrolled approximately 75 patients with treatment-resistant epilepsy. The double-blind, randomized, placebo-controlled clinical trial was designed to evaluate the safety, tolerability and clinical activity of VX-765.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.